Targeting AML-associated FLT3 mutations with a type I kinase inhibitor

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors in acute myeloid leukemia (AML) is often mediated by tyrosine kinase domain (TKD) mutations.
• FLT3 inhibitors are crucial for treating FLT3-mutant AML, but resistance remains a significant clinical challenge.

Purpose of the Study:

• To investigate the structural basis of NCGC1481 binding to FLT3, including resistance mutations.
• To evaluate the efficacy of NCGC1481 against FLT3-mutant AML cells, particularly those with acquired resistance mechanisms.

Main Methods:

• Cocrystallization of FLT3 with the type I inhibitor NCGC1481.
• Biochemical assays to assess binding affinity against wild-type and mutant FLT3.
• In vitro and in vivo studies using FLT3-mutant AML cell lines and patient-derived xenograft models.

Main Results:

• The cocrystal structure revealed potent binding of NCGC1481 to FLT3, including TKD and gatekeeper mutations.
• NCGC1481 demonstrated significant antileukemic activity against FLT3-mutant AML cells in vitro.
• Preclinical in vivo models showed superior efficacy of NCGC1481 compared to current FLT3 inhibitors.

Conclusions:

• NCGC1481 is a potent inhibitor of FLT3, effective against common resistance mutations.
• The drug exhibits promising antileukemic activity in preclinical models of FLT3-mutant AML.
• NCGC1481 represents a potential therapeutic strategy for overcoming resistance to existing FLT3 inhibitors in AML treatment.